Beam Therapeutics (BEAM) EBT (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of EBT data on file, last reported at -$98.3 million in Q1 2026.

• On a quarterly basis, EBT rose 10.25% year-over-year to -$98.3 million in Q1 2026; TTM through Mar 2026 was -$69.0 million, a 82.19% increase from a year earlier, with the FY2025 full-year figure at -$80.0 million, up 78.77% from the prior year.
• EBT for Q1 2026 stood at -$98.3 million, down from $244.3 million in the prior quarter.
• Over the last five years, EBT for BEAM reached as high as $244.3 million in Q4 2025 and fell as low as -$176.2 million in Q2 2022.
• Historically, EBT has averaged -$62.6 million across 5 years, with a median of -$92.7 million in 2024.
• Across the five-year window, EBT tumbled 190.44% in 2022 and jumped 485.99% in 2023, its largest moves.
• Year by year, EBT stood at -$37.3 million in 2022, then soared by 485.99% to $144.2 million in 2023, then plunged by 162.67% to -$90.4 million in 2024, then surged by 370.38% to $244.3 million in 2025, then tumbled by 140.24% to -$98.3 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$98.3 million in Q1 2026, $244.3 million in Q4 2025, and -$112.7 million in Q3 2025.